Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea; Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea.
Vaccine. 2020 Aug 27;38(38):6065-6073. doi: 10.1016/j.vaccine.2019.09.065. Epub 2019 Oct 4.
This study was performed to investigate the serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in Asian countries. A prospective surveillance study on S. pneumoniae collected from adult patients (≥50 years old) with invasive pneumococcal disease or community-acquired pneumonia was performed at 66 hospitals in Asian countries (Korea, China, Malaysia, Singapore, the Philippines, and Thailand) in 2012-2017. Serotyping and antimicrobial susceptibility tests of 850 pneumococcal isolates were performed. The proportions of isolates with serotypes covered by 13-valent pneumococcal conjugate vaccine (PCV13) were 37.0% in Korea, 53.4% in China, 77.2% in Malaysia, 35.9% in the Philippines, 68.7% in Singapore, and 60.2% in Thailand. Major serotypes were 19F (10.4%), 19A (10.1%), and 3 (8.5%) in 2012-2017, with different serotype distributions in each country. Macrolide resistance in pneumococci was high (66.8%) and prevalence of multidrug resistance (MDR) also remained high (50.8%). MDR non-PCV13 serotypes such as 11A, 15A, 35B, and 23A have emerged in Asian countries. This study showed the persistent prevalence of 19F and 19A with a noteworthy increase of certain non-PCV13 serotypes in Asian countries. High prevalence of macrolide resistance and MDR was also found in pneumococcal isolates. These data emphasize the need for continued surveillance of pneumococcal epidemiology in Asia in the post-pneumococcal vaccine era.
本研究旨在调查亚洲国家肺炎链球菌的血清型分布和抗菌药物敏感性。2012-2017 年,在亚洲 66 家医院(韩国、中国、马来西亚、新加坡、菲律宾和泰国)对患有侵袭性肺炎球菌病或社区获得性肺炎的成年患者(≥50 岁)进行了一项关于肺炎链球菌的前瞻性监测研究。对 850 株肺炎链球菌分离株进行了血清分型和抗菌药物敏感性试验。在韩国、中国、马来西亚、菲律宾、新加坡和泰国,13 价肺炎球菌结合疫苗(PCV13)覆盖血清型的分离株比例分别为 37.0%、53.4%、77.2%、35.9%、68.7%和 60.2%。2012-2017 年主要血清型为 19F(10.4%)、19A(10.1%)和 3(8.5%),每个国家的血清型分布不同。肺炎链球菌对大环内酯类药物的耐药率较高(66.8%),且多重耐药率(MDR)也居高不下(50.8%)。某些非 PCV13 血清型如 11A、15A、35B 和 23A 已在亚洲国家出现。本研究表明,19F 和 19A 的持续流行率较高,某些非 PCV13 血清型的流行率也有所上升。肺炎链球菌分离株中还发现了大环内酯类耐药和 MDR 高流行率。这些数据强调了在肺炎球菌疫苗时代,亚洲地区需要继续监测肺炎球菌的流行病学情况。